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Purpose. To evaluate the usefulness of microperimetry in the early detection of the ocular anomalies associated with the use of
hydroxychloroquine.Methods. Prospective comparative case series study comprising 14 healthy eyes of 7 patients (group A) and 14
eyes of 7 patients under treatment with hydroxychloroquine for the treatment of rheumatologic diseases and without fundoscopic
or perimetric anomalies (group B). A comprehensive ophthalmological examination includingmicroperimetry (MP) and spectral-
domain optical coherence tomography was performed in both groups. Results. No significant differences were found in mean MP
foveal sensitivity between groups (𝑃 = 0.18). However, mean MP overall sensitivity was significantly higher in group A (29.05 ±
0.57 dB versus group B, 26.05 ± 2.75 dB; 𝑃 < 0.001). Significantly higher sensitivity values were obtained in group A in comparison
to group B for the three eccentric loci evaluated (𝑃 < 0.001). Conclusion. Microperimetry seems to be a useful tool for the early
detection of retinal damage in patients treated with hydroxychloroquine.
1. Introduction
Hydroxychloroquine (HCQ) is the hydroxylated form of
chloroquine (CQ), an antimalarial drug used by rheumatolo-
gists for the treatment of various systemic diseases including
rheumatoid arthritis (RA) or systemic lupus erythematosus
(SLE). The potential ocular toxicity of HCQ [1] was well
known and was described first by Shearer and Dubois in 1967
[2]. The ocular side effects are less frequent and severe with
HCQ comparedwith CQ and include asthenopia, paracentral
scotoma, and color vision defects [3]. If those symptoms
are overlooked, early degeneration of the retinal pigmentary
epithelium (RPE) induced by HCQ can progress to an irre-
versible central visual loss. However, there is no agreement
in how to establish a routine protocol for the early diagnosis
of the HCQ retinopathy [4]. Likewise, new more sensitive
techniques are needed to detect early changes and minimize
visual loss. Microperimetry (MP) has demonstrated a wide
potential for prediction, detection, and treatmentmonitoring
in macular diseases [5]. This paper aims to evaluate the
usefulness of this technique in the early diagnosis of HCQ
maculopathy in asymptomatic patients with no fundoscopy
findings or perimetric losses.
2. Materials and Methods
2.1. Patients. This prospective comparative case series study
included a total of 28 eyes of 14 patients with ages ranging
from 21 to 62 years. Patients with any type of active ocular
disease or previous eye surgery were excluded. Two groups
of eyes were differentiated: group A included 14 healthy eyes
of 7 patients randomly selected and group B included 14
consecutive eyes of 7 patients using HCQ at least 1 year
before the examination (mean exposure 12.33 ± 16.79 years
(range 1 to 34 years)) and without fundoscopic or visual field
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alterations using a 10:2 threshold strategy (Humphrey Field
Analyzer, Carl Zeiss, Germany). After the perimetric exami-
nation, mean deviation (MD) and mean standard deviation
(MSD) were calculated. MD indicates the mean difference
between the normal expected retinal sensitivity in terms of
age and visual acuity and the measured patient sensitivity.
Likewise, MSD evaluates the changes of the visual field
pattern compared to the ideally expected ones in terms of
patient age.Thus, a highMSD implies a significant focal visual
field loss and a high probability of scotoma. All patients were
given a written informed consent to participate in this study,
which was approved by the local ethics committee. All the
procedures followed the tenets of the Declaration of Helsinki.
2.2. Examination Protocol. A comprehensive ophthalmolog-
ical examination was performed in all patients, including
manifest refraction, corrected distance visual acuity (CDVA),
slit-lamp examination, intraocular pressure (IOP), fun-
doscopy, MP, and spectral-domain optical coherence tomog-
raphy (SD-OCT). MP was performed with the microperime-
ter MAIA (Centervue, Padova, Italy), which integrates the
mechanism of the scanning laser ophthalmoscope (SLO)
with the static perimetry. The mechanism of observation is
an infrared superluminescent diode of wavelength 830 nm
(Laser Class I, 60825-1 IEC: 2007) which provides images of
high quality even with pupil diameters up to 2.5mm. The
maximum level of light of the perimetry is predetermined by
the source of laser until levels of 318.47 cd/m2 and appears
in ranges of attenuation from 0 to 36 dB in 1 dB steps. The
background luminance is 1.27 cd/m2. A Goldmann-type size
III stimulus is used in presentations of 200 milliseconds of
duration.
Themeasures of sensitivity with themicroperimeter were
obtained using the option “Expert Exam,” consisting of the
application of a 4-2 staircase strategy of threshold in a static
exam. This examination allowed us to obtain the value of the
threshold in each point in 1 dB steps. The type of predefined
grid used for the perimetry consisted of 37 projection posi-
tions distributed in three concentric circles around the center
placed at 1∘, 2∘, and 5∘ positions, containing 12 points each.
After the examination, the results of sensitivity in the different
positions evaluated and the average threshold (AT) were
plotted and compared with a normative database provided by
the instrument in order to classify the case as normal or not
(Figures 1(a) and 1(b)). MAIA microperimeter also provides
more specific information about the patient’s fixation pattern
obtained from the raw data, such as the bivariate contour
ellipse area (BCEA) that represents the area of the ellipse
that better fits the fixation points recorded during the mea-
surement and that is obtained after estimating the major and
minor axes of such ellipse. The area was estimated in square
degrees considering 63% and 95% of points.
2.3. Statistical Analysis. Data analysis was performed using
the software SPSS for Windows version 19.0 (SPSS Inc.,
Chicago, USA). Normality of data samples was evaluated by
means of the Kolmogorov-Smirnov and the Shapiro-Wilk
tests. When parametric analysis was possible, Student’s 𝑡-test
for paired data was used for comparisons between groups.
Table 1: Clinical characteristics of the two groups of the analyzed
sample.
Control group HCQ group
Age (years) 38.86 ± 12.56(21 to 62)
40.86 ± 10.49
(31 to 62)
Sphere (D) −0.20 ± 1.02(−2.25 to 1.25)
−0.52 ± 1.61
(−4.25 to 0.75)
Cylinder (D) −0.52 ± 0.83(−2.50 to 0.00)
−0.52 ± 0.95
(−2.75 to 0.00)
Spherical equivalent (D) −0.46 ± 0.94(−2.25 to 1.25)
−0.78 ± 2.04
(−5.63 to 0.38)
CDVA (decimal scale) 1.00 ± 0.00(1.00 to 1.00)
1.05 ± 0.16
(0.90 to 1.50)
Central thickness (𝜇m) 210.3 ± 42.3(181 to 306)
209.7 ± 18.2
(176 to 232)
Average thickness (𝜇m) 272.0 ± 14.6(258.9 to 301.3)
269.2 ± 14.7
(249.3 to 286.6)
Volume (mm3) 7.69 ± 0.41(7.32 to 8.52)
7.61 ± 0.41
(7.05 to 8.10)
CDVA: corrected distance visual acuity; D: diopters; 𝜇m: micrometers.
When parametric analysis was not possible, the Wilcoxon
rank sum test was applied to assess the significance of such
differences. Differences were considered to be statistically
significant when the associated 𝑃 value was <0.05.
3. Results
The clinical characteristics of patients included in the sample
are summarized in Table 1, represented by the mean values ±
SD (range). Age, refractive error, CDVA, and retinal thickness
data are provided for both study groups. No significant dif-
ferences between groups in age (𝑃 = 0.603), refractive error
(𝑃 = 0.352), or CDVA (𝑃 = 0.99) were detected. The analysis
ofOCT results showed no topographic changes and no signif-
icant differences between groups in central retinal thickness
(𝑃 = 0.24), mean retinal thickness (𝑃 = 0.887), or retinal
volume (𝑃 = 0.843).
Automated perimetric examination using a 10:2 threshold
strategy resulted in a MD of −2.26 ± 0.91 (range −3.33 to
−0.47) and a MSD of 1.19 ± 0.25 (range 0.79 to 1.54).
MeanMP foveal sensitivity was 26.86 ± 1.75 dB (range 24
to 29 dB) and 25.43 ± 2.65 dB (range 21 to 28 dB) in groups
A and B, respectively. This difference was not statistically
significant (𝑃 = 0.18). Mean MP overall sensitivity was
significantly higher in group A (29.05 ± 0.57 dB, range 27.9
to 29.8 dB) compared to group B (26.05 ± 2.75 dB, range 20.4
to 29 dB) (𝑃 < 0.001).
The mean MP threshold values obtained for each ring
were calculated for each patient in each group. These out-
comes are summarized in Table 2. Significantly higher values
were obtained in group A in comparison to group B for
the three different eccentricities evaluated (2∘, 6∘, and 10∘,
𝑃 < 0.001). Likewise, significantly higher values of MP peri-
foveal sensitivity were found in group A compared to group
B (28.04 ± 2.67 versus 25.29 ± 2.78 dB, 𝑃 < 0.01).
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Figure 1: Examples of sensitivity maps obtained with the MAIA MP system: (a) sensitivity map of a patient under treatment with HCQ
(group B); (b) sensitivity map of a healthy patient (group A).
Table 2: Mean retinal sensitivity in each ring of the grid presented
for the two groups of the analyzed sample for both groups.
Control group HCQ group 𝑃 value
Ring 1∘ (dB) 30.20 ± 1.02(28.67 to 32.17)
27.36 ± 2.64
(21.17 to 30) <0.01
Ring 2∘ (dB) 29.16 ± 0.50(28.17 to 29.83)
26.96 ± 2.65
(20.67 to 29.50) <0.01
Ring 5∘ (dB) 28.04 ± 0.67(26.50 to 28.92)
25.29 ± 2.78
(19.33 to 28) <0.01
dB: decibel.
The analysis of the fixation pattern showed no significant
differences (𝑃 = 0.069) between groups A and B. Specifically,
95% of BCEA was 2.42 ± 3.48∘2 (range 0.40 to 9.70∘2) and
2.44 ± 2.71∘2 (range 0.50 to 10.30∘2) in groups A and B,
respectively.
4. Discussion
Although uncommon, the incidence of CQ maculopathy is
estimated between 1 and 6% andHCQmaculopathy below 1%
[6]. HCQ toxicity mechanism is not yet fully understood, but
Rodriguez-Padilla et al. reported an early damage of the gan-
glion cells and their photoreceptors in the perifoveal region
[7]. The main risk factors for this toxicity include age, the
cumulative dose [8], length of treatment longer than 5 years
[9], and renal or liver disease that may increase the blood lev-
els of these drugs. Although toxicity seems to be independent
of daily dose and dose/kg ratio, this remains unclear. For this
reason, it has been suggested not to exceed a daily dose of
400mg forHCQor of 250mg forCQ [10]. Nevertheless, there
is high variability in the cumulative doses that lead to toxic
retinopathy [11] and the damage may appear even in those
patients with a low systemic risk profile. Also, a high risk of
progression of the retinal damage has been suggested despite
the cessation of the treatment [12] and a “point of no return”
for macular toxicity [13]. Thus, an individual and weight-
adapted dosing has been proposed tominimize the incidence
of retinal damage [14].
Currently, there is no “gold-standard” protocol of exami-
nation to confirm that there is ocular toxicity previous to the
onset of an irreversible damage. Screening recommendations
vary widely throughout the available scientific literature [15].
An exhaustive ocular examination is essential to establish a
baseline profile in a patient who is going to be treated with
HCQ and also to confirm if there is damage in an already
treated patient. It should include a full medical history, VA
with the best refractive correction, anterior segment biomi-
croscopy to detect cornea verticillata, and dilated fundoscopy
to carefully evaluate themacula, where early signs of bull’s eye
maculopathy might be present in a long-term treated patient.
Those changes are preceded by a loss of parafoveal sensitivity
diagnosed by means of visual field examination (VFE). The
recommended strategy is an automated threshold with a
white 10-2 pattern. Other more sensitive but less acces-
sible testing modes include multifocal electroretinography
(mfERG) that allows the determination of local cone and
bipolar cell activity at the posterior pole, fundus autofluores-
cence (FAF) imaging that may reveal the early deposition of
debris in the outer segments of photoreceptors, and SD-OCT
thatmay detect early thinning of the retinal layers in paracen-
tral areas [10]. Nevertheless, some doubts still arise regarding
these techniques. There is still not enough scientific evidence
of the usefulness of FAF in the early diagnosis of HCQ mac-
ulopathy [16], and mfERG and SD-OCT failed to identify a
significant number of cases of antimalarial retinal toxicity [17]
and thus cannot be considered as gold-standard techniques to
identify CQ and HCQmaculopathy.
Recently, the development ofMPhas allowed clinicians to
early identify a reduced paracentral retinal sensitivity in those
patients exposed toCQandHCQ.Angi et al. reported a single
case report showing a decreased sensitivity in an asymp-
tomatic 60-year-oldwomanwho had been receiving 3mgCQ
for 17 years for treating a severe RA. The patient showed a
granular appearance of the macula but CDVA of 1.0 (decimal
scale). Using the MP-1 microperimeter (Nidek Inc., Italy),
these authors found a dense scotoma within the central 12∘.
The authors highlighted the usefulness of this technique in
the follow-up as the tracking system allows the examination
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of exactly the same retinal points each time [18]. Mart´ınez-
Costa et al. conducted a controlled cross-sectional study in a
sample of 209 patients taking HCQ or CQ to compare the
microperimetric findings to 204 controls using the MAIA
microperimeter. They found a significant depression in reti-
nal sensitivity values in cases versus control subjects suggest-
ing the usefulness ofMP for the early detection of retinal tox-
icity [19]. Recently, these results have been corroborated by
Jivrajka et al. in 16 patients under a long-termHCQ treatment
andwithout clinical findings bymeans ofmfERG, FAF, or SD-
OCT techniques.They found a significant reduction of retinal
sensitivity compared to controls [20]. According to our
results, MP is a perimetric technique that provides enough
information about retinal sensitivity and can be considered as
a screening clinical procedure for the early detection of retinal
damage in patients treated with antimalarial drugs. It is
especially useful for detecting retinal alterations that cannot
be detected in the fundoscopic examination or by OCT.
Specifically, the obtained results, in absence of significant
damage in the 10:2 threshold strategy perimetry observed
in the study group of our sample, are the distinguishing
feature compared to the previous research and permit paving
the way for MP to become the gold-standard diagnostic
technique in the early diagnosis of HCQmaculopathy. Future
studies evaluating larger samples of eyeswould be desirable to
corroborate these results and to analyse if parafoveal changes
in retinal sensitivity begin immediately after the beginning of
the treatment.
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